학술논문

A phase i study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses

Document Type

Article

Author

Zimmer, A.S.; Nichols, E.; Kohn, E.C.; Annunziata, C.M.; Lipkowitz, S.; Mikkilineni, L.; Gatti-Mays, M.; Houston, N.D.; Lee, J.-M.; Cimino-Mathews, A.; Figg, W.D.; Sharma, R.; Peer, C.; Cao, L.; Lee, M.-J.; Trepel, J.B.

Source

In: Journal for ImmunoTherapy of Cancer. (Journal for ImmunoTherapy of Cancer, 25 July 2019, 7(1))

Subject

Language

English

ISSN

20511426

Online Access

Full Text (Gale Academic Onefile) Full Text (ProQuest Central) Open Access (EBSCO) Open Access (BioMed Central) Web of Science JCR 저널정보 Scopus Find it@PNU

이메일

부산대학교 도서관

Online Access

메일 발송